RxDoctor Payments Data

Tanja Noecker, PA

Medical · Lincoln, NENPI 1194733709

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 58.7% of the total.

$1,348in general payments, 2019–2025

Across 81 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$792
  • Novo Nordisk$211
  • Astellas Pharma US Inc$146
  • Lilly USA, LLC$44
  • Merck$36
  • AstraZeneca$31
  • plus $88 from 7 others

What the payments were for

  • Food & beverage$1,348100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,348 in reported general payments places this provider in the 70th percentile of 216 medical providers in Nebraska.

See all medical providers in Nebraska

Medicare billing

Part B allowed, 2024
$48,750
Medicare patients
169
Services billed
1,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$111,042
FarxigaDapagliflozin Propanediol43$41,700
MyrbetriqMirabegron45$35,274
JardianceEmpagliflozin25$31,124
XareltoRivaroxaban23$24,042
Nurtec OdtRimegepant Sulfate20$22,998
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$22,586
TrulicityDulaglutide16$20,276
SynthroidLevothyroxine Sodium37$2,989
Atorvastatin Calcium231$2,019
Fesoterodine Fumarate ErFesoterodine Fumarate13$2,005
Duloxetine Hcl71$1,886
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen60$1,865
Omeprazole138$1,835
Gabapentin102$1,697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$211$111,04293 claims
AstraZenecaFarxiga$31$41,70043 claims
Astellas Pharma US IncMyrbetriq$146$35,27445 claims
PfizerNurtec Odt$14$22,99820 claims
GSKTrelegy Ellipta$14$22,58629 claims
Lilly USA, LLCTrulicity$44$20,27616 claims
AbbVieSynthroid$792$2,98937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 216 medical providers in Nebraska.

Other medical in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →